Autonomix Medical, Inc. AMIX 深 滬
等待開盤 09-06 09:30:00 美东时间
1.1154
+0.040
+3.76%
華盛通- 最 高1.1377
- 今 開1.05
- 成交量 14.64万股
- 最 低 1.05
- 昨 收 1.075
- 總市值 573.95万
- 52周最高 21.49
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.9612
- 委 比 17.75%
- 總股本 514.57万
- 歷史最高 21.49
- 量 比 0.17
- 振 幅 8.16%
- 歷史最低 0.9612
- 每 手 1
- 風險率 4.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company, announced the release of a Virtual Investor "What This Means" segment featuring Dr. Robert Schwartz, its Chief Medical Officer. Dr. Schwartz discussed the company's recent post hoc analysis of its proof-of-concept human clinical trial ("PoC 1"), which showed sustained pain reduction, improved quality of life, and 100% opioid-free outcomes. The segment highlights the company's innov...
09-04 13:00
Autonomix Medical Announces Extended Post Hoc Data From First-In-Human Study On Transvascular Nerve Ablation For Pancreatic Cancer Pain Relief
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain100%
09-03 20:41
Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study
Autonomix Medical announced new data from its PoC 1 trial for treating severe pancreatic cancer pain, showing a 66% pain reduction (5.08 on VAS) and 100% opioid-free outcomes in responders at 3 months. Quality of life improvements included better sleep, energy, and daily activities. The company plans to expand into additional visceral cancers in PoC 2.
09-03 12:30
Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference
Autonomix Medical, Inc. announced that its CEO, Brad Hauser, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. Management will also hold one-on-one meetings with investors. A video webcast of the presentation will be available on September 8, 2025, and archived for 90 days. The company focuses on innovative technologies for diagnosing and treating nervous system diseases, initially t...
09-02 12:30
Autonomix Medical Raises Stock Sales Price
The latest announcement is out from Autonomix Medical, Inc. ( ($AMIX) ). Autono...
08-28 05:50
Autonomix Medical shares are trading higher after the company announced it entered into a $15 million purchase agreement.
Autonomix Medical shares are trading higher after the company announced it ente...
08-27 00:55
Autonomix Medical Enters $15M Purchase Agreement
An update from Autonomix Medical, Inc. ( ($AMIX) ) is now available. On August ...
08-26 18:59
Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.
Autonomix Medical, Inc. announced that Brad Hauser, President and CEO, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025, at 1:00 PM ET. The webinar, moderated by Jeffrey S. Cohen, will include a discussion and Q&A session. Interested participants can register online or submit questions in advance. The event will also be accessible via the Company’s website. Autonomix focuses on advancing precision ner...
08-18 13:15
Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Autonomix Medical, Inc. will present at the Webull Financial Corporate Connect Webinar Series on August 21, 2025, at 2:20 PM ET. Brad Hauser, President and CEO, will deliver the presentation. The company focuses on advancing precision nerve-targeted treatments and innovative technologies for nervous system diseases. Investor contact details are provided.
08-15 13:00
Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies
Autonomix Medical has advanced its proprietary sensing catheter through final design review, preparing for U.S. clinical trials. The device uses a microchip-based array to detect nerve signals in real time, enabling precise nerve targeting and treatment verification. This technology aims to enhance neuromodulation and pain management, addressing conditions like resistant hypertension and pancreatic cancer pain. The company is progressing toward s...
08-14 12:30
